Detalhe da pesquisa
1.
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Ann Oncol
; 30(10): 1613-1621, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31504118